$1.96
7.55% day before yesterday
NYSE, Dec 20, 10:07 pm CET
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Adc Therapeutics SA Stock price

$1.96
-0.02 1.01% 1M
-0.73 27.14% 6M
+0.30 18.07% YTD
+0.68 53.13% 1Y
-19.06 90.68% 3Y
-27.69 93.39% 5Y
-27.69 93.39% 10Y
NYSE, Closing price Fri, Dec 20 2024
-0.16 7.55%
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Key metrics

Market capitalization $189.51m
Enterprise Value $39.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.56
P/S ratio (TTM) P/S ratio 2.68
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -42.30%
Revenue (TTM) Revenue $70.72m
EBIT (operating result TTM) EBIT $-136.59m
Free Cash Flow (TTM) Free Cash Flow $-137.19m
Cash position $274.27m
EPS (TTM) EPS $-2.40
P/E forward negative
P/S forward 2.61
EV/Sales forward 0.55
Short interest 4.46%
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Adc Therapeutics SA forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Adc Therapeutics SA forecast:

Buy
86%
Hold
14%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
71 71
42% 42%
100%
- Direct Costs 8.28 8.28
0% 0%
12%
65 65
43% 43%
92%
- Selling and Administrative Expenses 86 86
19% 19%
122%
- Research and Development Expense 113 113
23% 23%
160%
-133 -133
4% 4%
-188%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -137 -137
4% 4%
-193%
Net Profit -212 -212
19% 19%
-300%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Positive
Seeking Alpha
9 days ago
Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expe...
Neutral
PRNewsWire
11 days ago
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Dec. ...
Neutral
PRNewsWire
13 days ago
Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma  shows ORR of 91% and 70% CR LAUSANNE, Switzerland , Dec. 9, 2024 /PRNewswire/ -- ADC Therapeutics SA (...
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 162
Founded 2011
Website www.adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today